ICON (ICLR) Aktievy
ICON Public Limited Company är en klinisk forskningsorganisation som tillhandahåller outsourcade utvecklings- och kommersialiseringstjänster på Irland, i övriga Europa, USA och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 5/6 |
| Framtida tillväxt | 1/6 |
| Tidigare resultat | 1/6 |
| Finansiell hälsa | 4/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
ICLR Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharmaceuticals & Biotech opportunity
LO
Fair Value from
US$7.675.4% undervärderad intrinsisk rabatt
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeICON Public Limited Company Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$125.00 |
| 52 veckors högsta | US$211.00 |
| 52 veckors lägsta | US$66.57 |
| Beta | 1.23 |
| 1 månads förändring | 16.65% |
| 3 månaders förändring | -16.99% |
| 1 års förändring | -9.73% |
| 3 års förändring | -37.22% |
| 5 års förändring | -44.96% |
| Förändring sedan börsintroduktionen | 1,865.56% |
Senaste nyheter och uppdateringar
Analysuppdatering • May 06
ICLR: Site Network Expansion Will Support Recovery From Accounting Investigation
ICON's updated analyst price target has moved higher to $135.07 from $132.08 as analysts weigh recent target hikes and upgrades against ongoing accounting related concerns and more cautious growth assumptions. Analyst Commentary Street research on Icon reflects a split view, with some analysts focusing on valuation support and long term demand for clinical research, while others stay cautious around accounting risks and reduced earnings assumptions.Analysuppdatering • Apr 22
ICLR: Oncology And Site Network Expansion Will Offset Accounting Overhang
ICON's updated analyst price target has shifted from about $142.86 to roughly $132.08 as analysts factor in lower modeled revenue growth, a slightly different discount rate, and a reduced future P/E, partly offset by a modestly higher profit margin outlook and mixed reactions to the recent accounting investigation and subsequent ratings changes. Analyst Commentary Recent research on ICON reflects a wide range of opinions as firms reassess the stock following the internal accounting investigation, reduced price targets, and updates to sector models in life science tools, diagnostics, and contract research organizations.
Analysuppdatering • Apr 07
ICLR: Accounting Review And Backlog Uncertainty Will Pressure Earnings Quality And Sentiment
Narrative update on ICON analyst targets Analysts have collectively reset ICON's average price target lower to around $120, citing ongoing accounting investigations and reduced sector targets. Some also highlight the possibility of upside if biopharma activity improves and current valuation already reflects much of the perceived risk.Analysuppdatering • Mar 24
ICLR: Accounting Investigation Will Drive Earnings Quality Concerns And Higher Perceived Risk
Narrative Update The analyst price target for ICON has been reset lower to $75.00 from $163.85 as analysts factor in higher perceived risk, more conservative growth and margin expectations, and sector wide target cuts following the company's internal accounting investigation and Q4 updates across life science tools and contract research peers. Analyst Commentary Recent Street research on ICON reflects a clear reset in expectations, with several firms cutting price targets and adjusting ratings following the internal accounting investigation and related uncertainty.Recent updates
Analysuppdatering • May 06
ICLR: Site Network Expansion Will Support Recovery From Accounting Investigation
ICON's updated analyst price target has moved higher to $135.07 from $132.08 as analysts weigh recent target hikes and upgrades against ongoing accounting related concerns and more cautious growth assumptions. Analyst Commentary Street research on Icon reflects a split view, with some analysts focusing on valuation support and long term demand for clinical research, while others stay cautious around accounting risks and reduced earnings assumptions.Analysuppdatering • Apr 22
ICLR: Oncology And Site Network Expansion Will Offset Accounting Overhang
ICON's updated analyst price target has shifted from about $142.86 to roughly $132.08 as analysts factor in lower modeled revenue growth, a slightly different discount rate, and a reduced future P/E, partly offset by a modestly higher profit margin outlook and mixed reactions to the recent accounting investigation and subsequent ratings changes. Analyst Commentary Recent research on ICON reflects a wide range of opinions as firms reassess the stock following the internal accounting investigation, reduced price targets, and updates to sector models in life science tools, diagnostics, and contract research organizations.Analysuppdatering • Apr 07
ICLR: Accounting Review And Backlog Uncertainty Will Pressure Earnings Quality And Sentiment
Narrative update on ICON analyst targets Analysts have collectively reset ICON's average price target lower to around $120, citing ongoing accounting investigations and reduced sector targets. Some also highlight the possibility of upside if biopharma activity improves and current valuation already reflects much of the perceived risk.Analysuppdatering • Mar 24
ICLR: Accounting Investigation Will Drive Earnings Quality Concerns And Higher Perceived Risk
Narrative Update The analyst price target for ICON has been reset lower to $75.00 from $163.85 as analysts factor in higher perceived risk, more conservative growth and margin expectations, and sector wide target cuts following the company's internal accounting investigation and Q4 updates across life science tools and contract research peers. Analyst Commentary Recent Street research on ICON reflects a clear reset in expectations, with several firms cutting price targets and adjusting ratings following the internal accounting investigation and related uncertainty.Analysuppdatering • Mar 10
ICLR: Oncology Expansion Will Offset Accounting Overhang And Reset Sentiment
The updated analyst price target for ICON moves lower to $142.86 from $154.86, with analysts citing accounting-related uncertainty and potential backlog restatements, partially balanced by views that the recent selloff and current valuation may offer a more compelling risk and reward profile. Analyst Commentary Recent research on ICON reflects a split view, with some analysts seeing value after the selloff and others emphasizing ongoing accounting and growth risks.Analysuppdatering • Feb 24
ICLR: Oncology Expansion And Accounting Overhang Are Expected To Reset Sentiment
Analysts have lowered their average price target on ICON from about $206 to roughly $155 as they factor in the ongoing internal accounting investigation, modestly softer growth and margin assumptions, a slightly higher discount rate, and a reduced future P/E multiple, even as some describe the recent share price weakness as creating a more compelling entry point. Analyst Commentary Recent research on ICON reflects a split view, with some analysts turning more constructive after the share price pullback while others remain cautious given the internal accounting investigation and softer growth and margin assumptions.Analysuppdatering • Feb 09
ICLR: Oncology Expansion And Contract Visibility Will Support Future Upside Potential
Narrative Update on ICON Analysts have modestly adjusted their stance on ICON, with recent target changes clustered in a US$11 range. These changes reflect mixed views on softer revenue growth visibility, margin pressure into 2026, and updated healthcare utilization trends.Analysartikel • Feb 06
It's Down 28% But ICON Public Limited Company (NASDAQ:ICLR) Could Be Riskier Than It Looks
ICON Public Limited Company ( NASDAQ:ICLR ) shares have had a horrible month, losing 28% after a relatively good period...Analysuppdatering • Jan 25
ICLR: Mixed Margin And Cancellation Signals Will Shape Fairly Balanced Outlook
The analyst price target for ICON has edged higher by about US$1 to US$206.38, as analysts factor in slightly adjusted assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E after a mix of recent target raises and trims across the Street. Analyst Commentary Recent research on ICON reflects a split view, with some on the Street lifting targets while others are turning more cautious as they reassess growth, margins, and contract visibility heading into 2026.Analysuppdatering • Jan 11
ICLR: Strong Bookings And RFP Momentum Will Offset Margin Concerns
Analysts have trimmed their ICON fair value estimate by about US$0.69 to roughly US$205.69. This reflects expectations of softer revenue growth, thinner margins and a slightly higher discount rate, while still using a somewhat higher future P/E assumption in line with recent price target revisions across the Street.Analysuppdatering • Dec 25
ICLR: Strong Bookings And RFP Momentum Will Support Long Term Upside
We nudge our ICON price target slightly higher to approximately $206.38 from about $206.19, as analysts balance continued concerns around 2026 margin pressure and pricing headwinds with updated post Q3 models and confidence that stronger gross bookings and RFP flow can support a healthier long term growth profile. Analyst Commentary Street research reflects a mixed but generally constructive stance on ICON, with price targets converging around the low to mid $200 range and a split between Hold and Outperform ratings.Analysuppdatering • Dec 11
ICLR: Bookings Momentum Will Offset 2026 Margin And Pricing Headwinds
Analysts have modestly trimmed their blended price target on ICON, reflecting a slightly lower valuation multiple as they balance ongoing concerns about 2026 margin and pricing headwinds, highlighted in recent target cuts such as TD Cowen's move to $172 from $183 and Leerink's to $220 from $235, against still-supportive views on bookings momentum and long term growth prospects. Analyst Commentary Bullish Takeaways Bullish analysts highlight that updated models following Q3 results support modest upside to fair value, even after factoring in near term margin noise.Analysuppdatering • Nov 27
ICLR: Bookings Momentum And Leadership Transition Will Drive Renewed Confidence In 2025
ICON’s analyst price target was revised modestly downward from $208.27 to $206.19, as analysts cited ongoing concerns about margin pressure and potential headwinds for 2026. These concerns were partially tempered by encouraging booking trends and updated financial models following recent quarterly results.Analysuppdatering • Nov 08
ICLR: Operational Resilience And Leadership Transition Will Support Momentum Next Year
The analyst price target for ICON has edged lower by approximately $0.67 to $208.27, as analysts cite ongoing concerns about margin pressure and a slightly more cautious revenue growth outlook. Analyst Commentary Analyst sentiment on ICON remains divided, with both encouraging signals and pressing concerns for investors to consider.Analysuppdatering • Oct 24
Margin Pressures And Partnership Wins Will Shape Next-Year Performance Outlook
The analyst fair value estimate for ICON has been revised downward by approximately $7 to $208.93. Analysts cite ongoing concerns about margin pressure and future revenue growth challenges.Seeking Alpha • Oct 22
ICON: Solid Fundamentals Trump Regulatory Headwinds
Summary In H1 2025, ICON's net book-to-bill ratio dropped to its lowest value since at least 2016. However, this ratio could improve since macroeconomic uncertainty is vanishing. ICON has a repurchase program of $1,000 million underway, which could buy approximately 6.90% of the company's outstanding common shares. Despite the challenging times, ICON is a profitable firm, has low debt, and presents symptoms of undervaluation compared to other CRO companies. Read the full article on Seeking AlphaAnalysuppdatering • Sep 13
Midsized Pharma Partnerships And AI Tools Will Streamline Operations
ICON’s consensus price target has been revised down from $220.40 to $215.67 as analysts express caution over persistent revenue and booking growth risks, customer cancellations, and macro uncertainty, which offset recent partnership gains and stable sector demand. Analyst Commentary Bearish analysts highlighted persistent revenue and EBITDA growth risks in 2026 tied to lower-than-normal book-to-bills (BtBs) and customer cancellations, with consensus estimates seen as too optimistic.Analysartikel • Aug 20
After Leaping 25% ICON Public Limited Company (NASDAQ:ICLR) Shares Are Not Flying Under The Radar
NasdaqGS:ICLR 1 Year Share Price vs Fair Value Explore ICON's Fair Values from the Community and select yours ICON...Analysartikel • Aug 12
Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 43%?
Key Insights ICON's estimated fair value is US$280 based on 2 Stage Free Cash Flow to Equity ICON's US$160 share price...Analysartikel • Jul 14
What Is ICON Public Limited Company's (NASDAQ:ICLR) Share Price Doing?
Today we're going to take a look at the well-established ICON Public Limited Company ( NASDAQ:ICLR ). The company's...Analysartikel • May 20
We Think ICON (NASDAQ:ICLR) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Feb 24
ICON: An Excellent Investment Opportunity With Strong Growth Potential
Summary ICON's revenues and net income have increased by 196.06% and 137.71%, respectively, between 2020 and 2024. Even though the CRO market expects a challenging outlook for 2025, in the next 9–10 years, the CRO market expects to grow at a 5.8%-7.42% CAGR. ICON has seen a decline in its non-current bank and loan debts of 36.88% since 2021. Its non-current bank and loan debts accounted for 57.74% of its liabilities in 2021. The price-to-book value of ICON has reached its lowest value in the last ten years. In addition, the EV/EBITDA ratio is close to its minimum value in ten years. Read the full article on Seeking AlphaSeeking Alpha • Dec 13
ICON: A High Probability Of Success In The Uncertain R&D Process
Summary Recent share price weakness is due to temporary headwinds, including client cost-cutting and delays in biotech decision-making, not structural issues in the CRO industry. Long-term prospects remain strong and structural growth drivers are still intact. Short-term headwinds led to attractive valuations, offering a compelling investment opportunity. Read the full article on Seeking AlphaSeeking Alpha • Nov 29
ICON: Disappointing Change In Trajectory (Rating Downgrade)
Summary Due to unforeseen headwinds and weakened growth outlook, ICLR's investment case has changed materially. Issues around capital allocation and a slowdown in reinvestment opportunities tempers the potential for earnings growth and returns on capital. ICLR's valuation multiples have contracted significantly, with EV/EBIT dropping from 42x to 18x since '22. Read the full article on Seeking AlphaSeeking Alpha • Jul 13
ICON: Deleveraging Complete, Now See 18% CAGR In Valuation To FY'26E (Rating Upgrade)
Summary ICON acquired PRA Health Sciences in a $12B deal in 2020, creating a new company. The stock has doubled since the acquisition, and could be worth $370-$400/share based on earnings estimates and excess earnings above assets of similar price and risk. Its strong order book, earnings leverage, and attractive valuations support a buy recommendation. Read the full article on Seeking AlphaAktieägarnas avkastning
| ICLR | US Life Sciences | US Marknad | |
|---|---|---|---|
| 7D | 5.6% | 1.8% | 2.1% |
| 1Y | -9.7% | 7.7% | 30.6% |
Avkastning vs industri: ICLR presterade sämre än US Life Sciences branschen som gav 7.7 % under det senaste året.
Avkastning vs Marknaden: ICLR presterade sämre än US marknaden som gav 30.6 % under det senaste året.
Prisvolatilitet
| ICLR volatility | |
|---|---|
| ICLR Average Weekly Movement | 14.9% |
| Life Sciences Industry Average Movement | 8.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stabil aktiekurs: ICLR s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: ICLR s veckovolatilitet har ökat från 10% till 15% under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1989 | 39,800 | Barry Balfe | www.iconplc.com |
ICON Public Limited Company, en klinisk forskningsorganisation, tillhandahåller outsourcade utvecklings- och kommersialiseringstjänster på Irland, i övriga Europa, i USA och internationellt. Företaget är specialiserat på strategisk utveckling, hantering och analys av program som stödjer olika stadier i den kliniska utvecklingsprocessen, från val av substans till kliniska studier i fas I-IV. Företaget erbjuder också tjänster inom klinisk utveckling, inklusive alla utvecklingsfaser, tjänster för godkännande före och efter godkännande, datalösningar samt tjänster för tillgång till kliniker och patienter, tjänster för hantering av kliniska prövningar, konsulttjänster och kontraktsbemanning samt kommersiella tjänster som omfattar strategi, planering och utformning av kliniska prövningar, genomförande av hela studien samt kommersialisering efter marknadsintroduktion.
ICON Public Limited Company Sammanfattning av grunderna
| ICLR grundläggande statistik | |
|---|---|
| Börsvärde | US$9.48b |
| Vinst(TTM) | US$599.48m |
| Intäkter(TTM) | US$8.10b |
15.9x
P/E-förhållande1.2x
P/S-förhållandeÄr ICLR övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| ICLR resultaträkning (TTM) | |
|---|---|
| Intäkter | US$8.10b |
| Kostnad för intäkter | US$5.82b |
| Bruttovinst | US$2.28b |
| Övriga kostnader | US$1.68b |
| Intäkter | US$599.48m |
Senast redovisade vinst
Sep 30, 2025
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 7.85 |
| Bruttomarginal | 28.15% |
| Nettovinstmarginal | 7.40% |
| Skuld/egenkapitalförhållande | 36.5% |
Hur har ICLR utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/07 20:24 |
| Aktiekurs vid dagens slut | 2026/05/07 00:00 |
| Intäkter | 2025/09/30 |
| Årlig intjäning | 2024/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
ICON Public Limited Company bevakas av 31 analytiker. 14 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Eric Coldwell | Baird |
| Douglas Tsao | Barclays |
| Luke Sergott | Barclays |